Radiopharm Completes Productive FDA End-of-Phase 2 Meeting for RAD101, Advancing to Phase 3 Readiness
RADX is trading near its 52-week low of $1.4 (3.6% below the low).
Summary
Radiopharm Theranostics announced the successful completion of its End-of-Phase 2 meeting with the FDA for RAD101, providing a clear regulatory pathway for pivotal development in brain metastases imaging.
Key Events · Product Development and Regulatory · RADX
-
FDA End-of-Phase 2 Meeting Completed
Radiopharm Theranostics successfully completed its End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) for RAD101, an investigational imaging agent for brain metastases.
-
Clear Regulatory Pathway Established
The meeting provided a constructive dialogue and a clear framework for RAD101's pivotal clinical development plan, reinforcing confidence in the program's potential.
-
Phase 3 Readiness Initiated
The company is immediately advancing Phase 3 readiness activities, including clinical and operational planning, in anticipation of receiving official FDA meeting minutes within 30 days.
-
Strategic Partnership Exploration
Radiopharm is evaluating opportunities to engage with potential strategic partners to maximize the clinical impact and long-term value of the RAD101 program.
Analysis · RADX · Life Sciences
Radiopharm Theranostics has successfully completed its End-of-Phase 2 meeting with the FDA for RAD101, an imaging agent for brain metastases. This constructive interaction provides a clear regulatory framework for the pivotal clinical development program, significantly de-risking the path to market for a key pipeline asset. This positive development is particularly important for the company, which has previously disclosed going concern warnings and low cash balances, and comes as the stock trades near its 52-week low. Advancing RAD101 to Phase 3 readiness and exploring strategic partnerships could be crucial for the company's financial stability and future growth.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 36.9% of the 1029 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.77%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RADX was trading at $1.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $22.9M. The 52-week trading range was $1.40 to $16.25. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.